Adjuvant Immunotherapy of Extensively Drug-Resistant Tuberculosis (XDR-TB) in Ukraine

Prihoda, Nathalia D.; Arjanova, Olga V.; Yurchenko, Larisa V.; Sokolenko, Nina I.; Vihrova, Lyudmila A.; Pylypchuk, Volodymyr S.; Фролов, В М; Kutsyna, Galyna A

doi:10.3923/crt.2009.9.14

Cited by 5 publications

(5 citation statements)

References 1 publication

Supporting

Mentioning

Contrasting

Order By: Relevance

“…These results are further supported by the effect of V5 in fever control. We have worked on immunotherapy of TB over past 10 years, which resulted in a dozen published clinical trials involving close to 1,200 individuals [17][18][19][20]. In these studies we have used oral botanical immunomodulator Dzherelo or Immunoxel.…”

Section: Discussionmentioning

confidence: 99%

Therapeutic Vaccination of Treatment-Failed TB Patients on “Palliative” Support Consisting of Isoniazid and Rifampicin

OV¹

2013

Mycobact Diseases

View full text Add to dashboard Cite

show abstract

Section: Discussionmentioning

confidence: 99%

Therapeutic Vaccination of Treatment-Failed TB Patients on “Palliative” Support Consisting of Isoniazid and Rifampicin

OV¹

2013

Mycobact Diseases

View full text Add to dashboard Cite

show abstract

“…Studies [4,8,23] were excluded after finding out that they were duplicate studies and therefore were results of a publication bias (studies published in two different journals using different titles). Furthermore, Prihoda et al [22] was excluded because the study used Immunoxel combined with other forms of immunotherapies. The details for exclusion of studies are provided in Table 1.…”

Section: Excluded Studiesmentioning

confidence: 99%

“…Prihoda et al [22] The study compared Dzherelo (Immunoxel) with other forms of immunotherapies (Svitanok and Lizorm) [22].…”

Section: Studymentioning

confidence: 99%

Dzherelo (Immunoxel) as adjunctive therapy to standard antituberculosis treatment in patients with pulmonary tuberculosis: a systematic review and meta-analysis of clinical trials

et al. 2021

View full text Add to dashboard Cite

Background Dzherelo (Immunoxel) is one of the few approved immunomodulators that has been shown to produce positive treatment outcomes in patients with tuberculosis (TB). The aim of this review was to assess the effectiveness of Immunoxel used as adjunct therapy with conventional anti-TB therapy for the treatment of pulmonary TB. Methods Comprehensive search was conducted in different major databases: PubMed (MEDLINE), EMBASE (OVID), Cochrane Central Register of Controlled Trials (CENTRAL), Scopus (Elsevier). We also searched Google Scholar along with trial registries and hand-searched the reference list of identified original research as well as review articles. Conference proceedings of relevant TB and lung disease annual conferences were also screened. Two independent authors extracted outcome data using a standardised extraction form. Relative risk (RR), mean difference (MD) and standardised mean difference (SMD) with a 95% confidence interval (CI) were used as measures of effect. We assessed certainty of evidence using GRADE. Results Six clinical trials, which met the criteria for the review, were identified, and these provided data for the review. Overall results from the six trials that compared antituberculosis treatment (ATT) alone versus ATT and Immunoxel, and ATT and placebo versus ATT and Immunoxel showed an increased number of patients becoming sputum-negative in the Immunoxel group (RR 3.19; 95% CI 2.44 to 4.17; 488 participants). There was also reduction in body temperature among patients receiving Immunoxel compared to ATT alone (MD −0.20, 95% CI −0.22 to −0.18, 345 participants). However, there were no differences in body weight changes across all the studies (MD 5.65; 95% CI −0.80 to 12.11; 382 participants). Conclusion Current evidence indicates that the use of Immunoxel as an adjunctive treatment in patients with pulmonary tuberculosis has the potential to enhance the efficacy of antituberculosis treatment. However, well-designed, conducted and adequately powered clinical trials are needed to establish the effectiveness of this adjunctive treatment. Systematic review registration PROSPERO registration number: CRD42019127823

show abstract

“…Studies [4,8,23] were excluded after nding out that they were duplicate studies and therefore were results of a publication bias (studies published in two different journals using different titles). Furthermore, Prihoda et al [22] was excluded because the study used Immunoxel combined with other forms of immunotherapies. The details for exclusion of studies are provided in Table 1.…”

Section: Excluded Studiesmentioning

confidence: 99%

“…The study compared Dzherelo (immunoxel) with other forms of immunotherapies (Svitanok, and Lizorm) [22].…”

Section: Prihoda 2009mentioning

confidence: 99%

Dzherelo (Immunoxel) as Adjunctive Therapy to Standard Antituberculosis Treatment in Patients with Pulmonary Tuberculosis: A Systematic Review and Meta-analysis of Clinical Trials

Kitenge

Phiri

Pheeha

et al. 2020

Preprint

View full text Add to dashboard Cite

BackgroundDzherelo (Immunoxel) is one of the few approved immunomodulators that has been shown to produce positive treatment outcomes in patients with tuberculosis (TB). The aim of this review was to assess the effectiveness of Immunoxel used as adjunct therapy with conventional anti-TB therapy for the treatment of pulmonary TB. MethodsComprehensive search was conducted in different major databases: Pubmed (MEDLINE), EMBASE (OVID), Cochrane Central Register of Controlled Trials (CENTRAL), SCOPUS (Elsevier). We also searched Google Scholar along with trial registries and hand-searched the reference list of identified original research as well as review articles. Conference proceedings of relevant TB and lung diseases annual conferences were also screened. Two independent authors extracted outcomes data using a standardized extraction form. Relative risk (RR), mean difference (MD) and standardised mean difference (SMD) with a 95% confidence interval (CI) were used as measures of effect. We assessed certainty of evidence using GRADE.ResultsSix clinical trials, which met the criteria for the review were identified and these provided data for the review. Overall results from the six trials that compared anti-tuberculosis treatment (ATT) alone versus ATT and Immunoxel, ATT and Placebo versus ATT and Immunoxel, showed an increased number of patients becoming sputum-negative in the Immunoxel group (RR 3.19; 95% CI 2.44 to 4.17; 488 participants). There was also great reduction in body temperature among patients receiving Immunoxel compared to ATT alone (MD -0.20, 95% CI -0.22 to -0.18, 345 participants). However, there were no differences in body weight changes across all the studies (MD 5.65; 95% CI: -0.80 to 12.11; 382 participants). ConclusionCurrent evidence indicates that the use of Immunoxel as an adjunctive treatment in patients with pulmonary tuberculosis has the potential to enhance the efficacy of anti-tuberculosis treatment. However, well-designed, conducted and adequately powered clinical trials are needed to establish the effectiveness of this adjunctive treatment. PROSPERO registration number: CRD42019127823

show abstract

Adjuvant Immunotherapy of Extensively Drug-Resistant Tuberculosis (XDR-TB) in Ukraine

Cited by 5 publications

References 1 publication

Therapeutic Vaccination of Treatment-Failed TB Patients on “Palliative” Support Consisting of Isoniazid and Rifampicin

Therapeutic Vaccination of Treatment-Failed TB Patients on “Palliative” Support Consisting of Isoniazid and Rifampicin

Dzherelo (Immunoxel) as adjunctive therapy to standard antituberculosis treatment in patients with pulmonary tuberculosis: a systematic review and meta-analysis of clinical trials

Dzherelo (Immunoxel) as Adjunctive Therapy to Standard Antituberculosis Treatment in Patients with Pulmonary Tuberculosis: A Systematic Review and Meta-analysis of Clinical Trials

Contact Info

Product

Resources

About